Table 6.
Pharmacokinetic parameters of marketed and optimized lamivudine controlled release tablet (F7) after a single oral dose of 100 mg lamivudine to rabbits (n = 3).
| Pharmacokinetic parameters | Observed value (Lamivir®) | Observed value (F7) |
|---|---|---|
| Maximum plasma concentration, Cmax (ng/mL) | 12,784.91 ± 2.1 | 8342.56 ± 3.4 |
| Time required to reach maximum plasma concentration, Tmax (h) | 1.00 ± 1.6 | 4.00 ± 2.2 |
| Area under curve at 24 h, AUC(0 → ∞) (ng h/mL) | 54,206.284 ± 3.7 | 57,075.323 ± 4.5 |
| Area under momentum curve at 24 h, AUMC(0 → ∞) (ng h2/mL) | 227,067.968 ± 0.6 | 306,847.633 ± 1.2 |
| Volume of distribution, Vd (L) | 9.574 ± 2.8 | 16.910 ± 3.1 |
| Plasma half life, T1/2 (h) | 3.594 ± 0.2 | 6.690 ± 4.1 |
| Absorption rate constant, Ka (h−1) | 2.142 ± 1.8 | 0.796 ± 1.0 |
| Elimination rate constant, Ke (h−1) | 0.193 ± 1.5 | 0.105 ± 2.4 |
| Mean residence time, MRT (h) | 4.189 ± 2.1 | 5.376 ± 2.1 |
| Clearance, Cl (L/h) | 1.846 ± 3.0 | 1.753 ± 1.7 |